focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Ahhh. Now a note showing 02945 is to be used temporarily due to a corporate event.
I wait to see what happens next ;-)
Now this has happened, will this poss lead to some operational update announcements this week. We can but hope….lol
So the numbers have changed from today by a factor of 20.
What is also interesting is, unlike the previous consolidation, the stock number has also changed, now 02945. I wonder why ?
Sp currently 0.82HK$, obviously with the same market cap as last Friday and of course lot number has decreased to 500 from 10k
Morning The.Italain. I can't argue with that. :-)
The company needs to close the phase II out and have a license agreement in place in the next 6 months otherwise I see no hope without yet another loan from JM. Of course this will depend on how any license agreement is written which would require an upfront payment including the costs for the phase lll and follow through to approval.
It’s interesting that a Chinese licensee was willing to step up to the plate in a short period of time and back it, yet not one US licensee was willing to do so even with it being supposedly the jewel in the crown as far as markets go.
Dougie. Nail on the head.
What is interesting is under RPG/ERP and back to RPGs control, the FDA process started at the beginning of 2014 and up to today they still have not closed out the phase II (an unprecedented 9years). Yet the Chinese process which effectively started on Dec 3rd 2018 when the license agreement was entered into and the start of the process became controlled by Wangbang, they have done it in half the time. They are soon to submit the phase 3 results with possible approval in the following 12 months (5 years) and that’s including a 1 year delay due to RPG not making sure the authorities had all relevant information.
This certainly shows how broken the machinations of the company and its workforce truly are.
As expected all resolution convincingly passed, including JG as CEO. Unfortunately it won’t do the company any good since he knows nothing about nothing….lol
That should have been. “as usual their timelines….”
I would hazard a guess the sellers are fed up waiting for news. The FDA decision is taking far far longer than it should, as uheir timelines are made by amateurs.
Back to a market heading back to 16mill squid when the DLI started. The only difference now is there are twice as many shares in play.
I wonder what the DLI investors must be making of it since I’m sure promises must have been made regarding their investment during the takeover. They are now down about 70% if they didn’t take their rights.
Looks quite comprehensive, however, They cannot get their figures right. At the beginning the forecast for 2030 is over 4bill, yet at the end in the table, they state 2030 as 2,49bill which is only for 1 years growth at 8.5%. They should have gotten someone to read it first before uploading it. Makes one wonder if all the other figures need checking....lol
What is interesting is Levitra which seems to have an annual increase in market share from 2021 to 2027. What's so special about their product that it would appear to be gradually, year on year, cornering the market ?
But then Life itself is a gamble.
And of course it's a gamble since news of the phase iii start and a possible license agreement, plus possible news on China submission could scupper your plans. Thats if you do intend to buy several million :'O
As I wrote, a handful of shares ;-)
Depends how one looks at it doesn't it ?
If you are only buying a handful of shares, you will get them cheap, but if one had several million which they would have automatically got the rights to, no problem. Try buying several million and see what price you get them for.
Yes, all very true. I really don’t think they will upscale or even consider another manufacturing line (if that is at all possible) before they see demand, although Taiwan etc will also need a supply which even upscaling, I’m sure, still won’t be enough. A bit chicken and egg now given they must be apprehensive based on the original sales figures.
OTC ;-)
Afternoon The.Italian,
I notice both FUM and MHC(testing kits) both have agreements with boots (MHC just announced a new tie up) which, given boots have 2000+ outlets could be quite lucrative. Yet Recordati seems to be dragging their feet. I don’t actually recall any boots tie up when the product was only prescription.
Do you think they may get into some agreement now it’s ?
In the April Op update where the SPA is mentioned, JG mention phase iii studies twice indicating more than 1 is required, which are to start after the EOP2 meeting. As such, I really don’t expect an update till then, unless the SPA leads to a license agreement which I doubt considering the marketing exercise 3 years ago has led to absolutely nuffin either.
It certainly appears they are clutching at straws now looking at ways to convince a licensee to sign, particularly since not one licensee was willing to take a small risk to sign a license supposedly worth many tens of millions.
The.Italian, they are probably the same, although alluding to finishing a phase iii meaning an imminent NDA submission, 3 years ahead of schedule, could be considered, depending who you talk to, as being fraudulent.